Zylet is a drug owned by Bausch And Lomb Inc. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 25, 2014. Details of Zylet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5540930 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(11 years ago) |
Expired
|
|
US5747061 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(11 years ago) |
Expired
|
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(12 years ago) |
Expired
|
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(12 years ago) |
Expired
|
|
US4996335 (Pediatric) | Soft steroids having anti-inflammatory activity |
Sep, 2012
(13 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Zylet is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zylet's family patents as well as insights into
ongoing legal events
on those patents.
Zylet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zylet's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 25, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zylet Generics:
There are no approved generic versions for Zylet as of now.
About Zylet
Zylet is a drug owned by Bausch And Lomb Inc. It is used for treating inflammatory ocular conditions when a corticosteroid is needed and there is a risk of bacterial infection. Zylet uses Loteprednol Etabonate; Tobramycin as an active ingredient. Zylet was launched by Bausch And Lomb in 2004.
Approval Date:
Zylet was approved by FDA for market use on 14 December, 2004.
Active Ingredient:
Zylet uses Loteprednol Etabonate; Tobramycin as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate; Tobramycin ingredient
Treatment:
Zylet is used for treating inflammatory ocular conditions when a corticosteroid is needed and there is a risk of bacterial infection.
Dosage:
Zylet is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5%;0.3% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |